首页 | 本学科首页   官方微博 | 高级检索  
检索        

吸入粉雾剂产品的开发要点
引用本文:张成飞,李岩峰,杜晓英,任树龙,周振泽,王爱潮,李静.吸入粉雾剂产品的开发要点[J].现代药物与临床,2019,42(12):2314-2318.
作者姓名:张成飞  李岩峰  杜晓英  任树龙  周振泽  王爱潮  李静
作者单位:天津药业研究院有限公司, 天津 300386,天津药业研究院有限公司, 天津 300386,天津药业研究院有限公司, 天津 300386,天津药业研究院有限公司, 天津 300386,天津药业研究院有限公司, 天津 300386,天津药业研究院有限公司, 天津 300386,天津金耀集团有限公司, 天津 300450
基金项目:国家科技部重大专项(2017ZX09201002)
摘    要:吸入粉雾剂是药械组合药品,制剂和装置共同决定了产品的质量和雾化性能。在装置的开发中,需要关注使用装置的类型,与制剂处方联合开发;在制剂开发中,要关注粉体的粒度分布、颗粒形态、流动性、比表面积、多晶型及结晶度,提高对物化性质的认识。在产品的检测中,不仅要关注质量标准的检测项目,还要从患者的角度出发考察产品的雾化性能,以满足不同患者的使用。从装置的开发、制剂处方的研发以及质量控制3个方面阐述了吸入粉雾剂产品开发中需要重点关注的内容,以提高粉雾剂产品研发速度和质量。

关 键 词:吸入粉雾剂  吸入装置  雾化性能  质量控制
收稿时间:2019/9/30 0:00:00

Development points of dry powder inhalations
ZHANG Chengfei,LI Yanfeng,DU Xiaoying,REN Shulong,ZHOU Zhenze,WANG Aichao and LI Jing.Development points of dry powder inhalations[J].Drugs & Clinic,2019,42(12):2314-2318.
Authors:ZHANG Chengfei  LI Yanfeng  DU Xiaoying  REN Shulong  ZHOU Zhenze  WANG Aichao and LI Jing
Institution:Tianjin Pharmaceutical Research Institute Co., Ltd., Tianjin 300386, China,Tianjin Pharmaceutical Research Institute Co., Ltd., Tianjin 300386, China,Tianjin Pharmaceutical Research Institute Co., Ltd., Tianjin 300386, China,Tianjin Pharmaceutical Research Institute Co., Ltd., Tianjin 300386, China,Tianjin Pharmaceutical Research Institute Co., Ltd., Tianjin 300386, China,Tianjin Pharmaceutical Research Institute Co., Ltd., Tianjin 300386, China and Tianjin KingYork Group Co., Ltd., Tianjin 300450, China
Abstract:Dry Powder Inhalations (DPIs) are a combination of drug substance and container closure system, which determine the quality and performance of the products. It''s the focus that the type of device, which is the connection point between the patient and the preparation. The physicochemical properties of API and excipients, involved particle size distribution, shape, flow properties, specific surface area, polymorphism and crystallinity, are the critical research content. In the detection of DPIs, we should not only pay attention to the items of quality standards, but also the atomization performance of products from the perspective of patients. The development of device, formulation and the quality control of DPIs were discussed in the review. Focusing on these aspects can improve the progress of development and the quality of DPI products.
Keywords:DPIs  device  aerosol performance  quality control
点击此处可从《现代药物与临床》浏览原始摘要信息
点击此处可从《现代药物与临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号